Cambiar Investors LLC Cuts Stake in Maximus, Inc. (NYSE:MMS)

Cambiar Investors LLC reduced its position in shares of Maximus, Inc. (NYSE:MMS - Free Report) by 13.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 114,120 shares of the health services provider's stock after selling 17,850 shares during the quarter. Cambiar Investors LLC owned 0.19% of Maximus worth $8,519,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new stake in shares of Maximus during the 3rd quarter valued at $25,000. UMB Bank n.a. grew its stake in shares of Maximus by 79.8% during the 4th quarter. UMB Bank n.a. now owns 356 shares of the health services provider's stock valued at $27,000 after acquiring an additional 158 shares during the period. Eastern Bank purchased a new stake in Maximus in the 4th quarter worth approximately $29,000. R Squared Ltd bought a new stake in Maximus during the 4th quarter worth approximately $54,000. Finally, GAMMA Investing LLC lifted its holdings in Maximus by 150.6% during the third quarter. GAMMA Investing LLC now owns 862 shares of the health services provider's stock valued at $80,000 after purchasing an additional 518 shares in the last quarter. Hedge funds and other institutional investors own 97.21% of the company's stock.

Maximus Price Performance

Shares of Maximus stock traded down $2.02 during trading hours on Tuesday, reaching $67.68. The company's stock had a trading volume of 631,287 shares, compared to its average volume of 729,188. The stock has a market cap of $3.87 billion, a P/E ratio of 14.55 and a beta of 0.72. Maximus, Inc. has a one year low of $67.20 and a one year high of $93.97. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.72 and a quick ratio of 1.49. The firm has a 50 day moving average price of $74.64 and a 200-day moving average price of $83.12.

Maximus (NYSE:MMS - Get Free Report) last released its earnings results on Thursday, February 6th. The health services provider reported $1.61 EPS for the quarter, beating analysts' consensus estimates of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%. On average, analysts predict that Maximus, Inc. will post 6.05 EPS for the current year.

Maximus Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Shareholders of record on Saturday, February 15th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.77%. The ex-dividend date is Friday, February 14th. Maximus's dividend payout ratio (DPR) is 25.81%.

Insider Transactions at Maximus

In other Maximus news, insider Michelle F. Link sold 2,208 shares of Maximus stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $73.83, for a total value of $163,016.64. Following the transaction, the insider now directly owns 6,567 shares of the company's stock, valued at approximately $484,841.61. The trade was a 25.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce Caswell purchased 3,500 shares of the firm's stock in a transaction on Tuesday, December 17th. The stock was acquired at an average price of $70.64 per share, with a total value of $247,240.00. Following the completion of the purchase, the chief executive officer now owns 275,929 shares of the company's stock, valued at $19,491,624.56. The trade was a 1.28 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 7,063 shares of company stock valued at $502,017. Company insiders own 1.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MMS shares. StockNews.com upgraded Maximus from a "hold" rating to a "buy" rating in a research note on Thursday, February 6th. Raymond James raised shares of Maximus from a "market perform" rating to an "outperform" rating and set a $90.00 price objective for the company in a report on Thursday, January 2nd.

Maximus Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.